Adicet Bio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Adicet Bio is gedaald met een gemiddeld jaarlijks percentage van -34.8%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.1%. De inkomsten zijn daalde met een gemiddeld percentage van 14.9% per jaar.

Belangrijke informatie

-34.8%

Groei van de winst

30.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-14.9%
Rendement op eigen vermogen	-55.7%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Jul 12

Adicet Bio: Microcap With A High Risk To Reward Ratio

May 23

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 01

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Dec 20

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Oct 17

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Oct 04

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Aug 16

Adicet Bio: A First Take

Jul 22

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Jul 07

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

May 15

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Mar 18

Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate

Feb 09

Opbrengsten en kosten

Hoe Adicet Bio geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:ACET Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	0	-118	28	101
30 Jun 24	0	-137	27	101
31 Mar 24	0	-140	27	103
31 Dec 23	0	-143	27	106
30 Sep 23	0	-143	26	106
30 Jun 23	0	-115	26	97
31 Mar 23	0	-105	26	85
31 Dec 22	25	-70	26	71
30 Sep 22	30	-56	26	61
30 Jun 22	34	-48	25	56
31 Mar 22	39	-36	23	50
31 Dec 21	10	-62	22	48
30 Sep 21	10	-55	14	42
30 Jun 21	9	-56	16	39
31 Mar 21	12	-54	19	38
31 Dec 20	18	-37	16	34
30 Sep 20	14	-34	20	31
30 Jun 20	4	-34	14	29
31 Mar 20	0	-28	9	26
31 Dec 19	1	-28	9	24
31 Dec 18	8	-9	8	15

Kwaliteitswinsten: ACET is momenteel verliesgevend.

Groeiende winstmarge: ACET is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ACET is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 34.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van ACET over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: ACET is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: ACET heeft een negatief Return on Equity ( -55.73% ), omdat het momenteel verliesgevend is.

Adicet Bio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

Recent updates

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio: Microcap With A High Risk To Reward Ratio

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Price target decreased by 18% to US$12.80

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Price target decreased by 15% to US$18.29

New minor risk - Market cap size

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Price target decreased by 14% to US$23.29

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 180%, EPS downgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Chief Technology Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Consensus forecasts updated

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

CEO, President & Director notifies of intention to sell stock

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Now 23% undervalued after recent price drop

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Adicet Bio: A First Take

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

Consensus revenue estimates increase by 42%

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

High number of new and inexperienced directors

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Chief Medical Officer & Senior VP notifies of intention to sell stock

Consensus forecasts updated

Consensus revenue estimates fall by 31%

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Full year 2021 earnings: EPS and revenues exceed analyst expectations